Stocktwits on MSN
Theriva™ Biologics reports full-year 2025 operational highlights and financial results
Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma – – Licensed SYN-020 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results